TULIP study - to understand the roles of IL-17A & IL-17F in psoriasis

  • Research type

    Research Study

  • Full title

    To Understand the roles of interleukin (IL) 17A and IL-17F in the pathogenesis of psoriasis (TULIP) study.

  • IRAS ID

    236496

  • Contact name

    Jingyuan Xu

  • Contact email

    jingyuan.xu@manchester.ac.uk

  • Sponsor organisation

    University of Manchester

  • Duration of Study in the UK

    3 years, 6 months, 5 days

  • Research summary

    Psoriasis is a chronic disabling disease affecting nearly 2 million people in the UK, it is characterised by raised, red and scaly patches on the skin. It is not just a skin condition; psoriasis is associated with psoriatic arthritis, and other serious health conditions, such as diabetes and heart disease. While we do not know what causes psoriasis, we do know that the immune system plays a major part in its development.

    The TULIP (To Understand the roles of IL-17A & IL-17F In Psoriasis) study aims to investigate whether Interleukin (IL)-17, a chemical that the immune system produces, is important in psoriasis and a rare variant of psoriasis called pustular psoriasis. Healthy volunteers and patients with psoriasis and/or pustular psoriasis will be invited to take part in the study from dermatology outpatient clinics and established healthy volunteer database.

    Small skin samples and blood will be collected from participants to explore the expression of IL-17A and IL-17F and correlate this with:
    • Clinical phenotype (i.e. are there differences between subtypes of psoriasis?);
    • Disease severity; and
    • Treatment response.

    By understanding the roles of IL-17F and its other family members, which there are 6 in total including IL-17A, it will help us to develop more effective medicines by tailoring to the individual patient. Furthermore, the results are likely to give more valuable information on other diseases where IL-17 is involved.

    The TULIP study is a funded PhD project as part of the North West England Medical Research Council Clinical Research Fellowship Scheme in Clinical Pharmacology and Therapeutics.

  • REC name

    North West - Greater Manchester East Research Ethics Committee

  • REC reference

    18/NW/0632

  • Date of REC Opinion

    27 Sep 2018

  • REC opinion

    Favourable Opinion